Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery

Abstract Complete encapsulation of nucleic acids by lipid‐based nanoparticles (LNPs) is often thought to be one of the main prerequisites for successful nucleic acid delivery, as the lipid environment protects mRNA from degradation by external nucleases and assists in initiating delivery processes. However, delivery of mRNA via a preformed vesicle approach (PFV‐LNPs) defies this precondition. Unlike traditional LNPs, PFV‐LNPs are formed via a solvent‐free mixing process, leading to a superficial mRNA localization. While demonstrating low encapsulation efficiency in the RiboGreen assay, PFV‐LNPs improved delivery of mRNA to the retina by up to 50% compared to the LNP analogs across several benchmark formulations, suggesting the utility of this approach regardless of the lipid composition. Successful mRNA and gene editors’ delivery is observed in the retinal pigment epithelium and photoreceptors and validated in mice, non‐human primates, and human retinal organoids. Deploying PFV‐LNPs in gene editing experiments result in a similar extent of gene editing compared to analogous LNP (up to 3% on genomic level) in the Ai9 reporter mouse model; but, remarkably, retinal tolerability is significantly improved for PFV‐LNP treatment. The study findings indicate that the LNP formulation process can greatly influence mRNA transfection and gene editing outcomes, improving LNP treatment safety without sacrificing efficacy.